The treatment of melanoma brain metastases before the advent of targeted therapies: Associations between therapeutic choice, clinical symptoms and outcome with survival

Melanoma Research

Volumn 24, Issue 1, 2014, Pages 61-67

  Vecchio, Stefania ^a   Spagnolo, Francesco ^a   Merlo, Domenico F ^a   Signori, Alessio ^b   Acquati, Mirko ^c   Pronzato, Paolo ^a   Queirolo, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Brain metastases; melanoma; stereotactic radiosurgery

Indexed keywords

DACARBAZINE; FOTEMUSTINE; LOMUSTINE; TEMOZOLOMIDE;

ADULT; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MULTIPLE REGRESSION; NEUROIMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME;

BRAIN NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84891947779     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000029     Document Type: Article

References (38)

1. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 8:11-20.
2. De la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983; 43:4327-4333.
3. Nayak L, Quant Lee E, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012; 14:48-54.
4. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-1836.
5. Gupta G, Robertson AG, Mackie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997; 76:256-259.
6. McWilliams RR, Rao RD, Brown PD, Link MJ, Buckner JC. Treatment options for brain metastases from melanoma. Expert Rev Anticancer Ther 2005; 5:809-820.
7. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22:2101-2107.
8. Sul J, Posner JB. Brain metastases: epidemiology and pathophysiology. Cancer Treat Res 2007; 136:1-21.
9. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996; 78:1781-1788.
10. Wroński M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000; 93:9-18.
11. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43:795-803.
12. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10:199-207.
13. Peruzzi P, Chiocca EA. Prognosis and treatment of melanoma metastases to the central nervous system: lots of retrospective data, very few certainties. World Neurosurg 2011; 76:48-50.
14. Eighntler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate dehydrogenase level and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2010; 117:1697-1703.
15. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2010; 117:1687-1696.
16. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218.
17. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011; 117:1711-1720.
18. Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long term survival with metastatic cancer to the brain. Med Oncol 2000; 17:279-286.
19. Black PM, Johnson MD. Surgical resection for patients with solid brain metastases: current status. J Neurooncol 2004; 6:119-124.
20. Kalkanis SN, Kondziolka D, Gaspar LE. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:33-43.
21. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper Ekkehard, Eton O, Wong E. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 2012; 12:1207-1215.
22. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:45-68.
23. Williams J, Enger C, Wharam M, Tsai D, Brem H. Stereotactic radiosurgery for brain metastases. Comparison of lung carcinoma versus non-lung tumors. J Neurooncol 1998; 37:79-85.
24. Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, Bonerandi JJ, et al. Gamma-knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65:809-816.
25. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:17-32.
26. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29:134-141.
27. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013; 31:65-72.
28. Mehta MP, Paleologos NA, Mikkelsen T. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 71-83.
29. Tarhini AA, Agarwala SS. Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004; 16:161-166.
30. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
31. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
32. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 2012; 12:1207-1215.
33. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-6688.
34. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008; 5:557-561.
35. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010; 20:247-250.
36. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
37. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-233.
38. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.